{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T16:48:36Z","timestamp":1793378916178,"version":"4.5.0"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T00:00:00Z","timestamp":1613088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Breast cancer patients historically benefitted from population-based genetic research performed in South Africa, which led to the development of founder-based <jats:italic>BRCA1\/2<\/jats:italic> diagnostic tests. With the advent of next-generation sequencing (NGS) technologies, the clinical utility of limited, targeted genetic assays were questioned. The study focused on mining NGS data obtained from an extensive single-institution NGS series (n=763). The aims were to determine (i) the prevalence of the most common recurrent\/founder variants in patients referred for NGS directly; and (ii) to explore the data for inferred haplotypes associated with previous and potential new recurrent\/founder variants. The identification of additional founder variants was essential for promoting and potentially advancing to rapid founder-based <jats:italic>BRCA1\/2<\/jats:italic> point-of-care (POC) technology as a time- and cost-effective alternative. NGS revealed actionable <jats:italic>BRCA1\/2<\/jats:italic> variants in 11.1% of patients tested (<jats:italic>BRCA1<\/jats:italic> \u2013 4.7%; <jats:italic>BRCA2<\/jats:italic> \u2013 6.4%), of which 22.4% represented variants currently screened for using first-tier targeted genetic testing. A retrospective investigation into the overall mutation-positive rate for an extended cohort (n=1906), which included first-tier test results, revealed that targeted genetic testing identified 74% of all pathogenic variants. This percentage justified the use of targeted genetic testing as a first-tier assay. Inferred haplotype analysis confirmed the founder status of <jats:italic>BRCA2<\/jats:italic> c.5771_5774del (rs80359535) and c.7934del (rs80359688) and revealed an additional African founder variant (<jats:italic>BRCA2<\/jats:italic> c.582G&amp;gt;A \u2013 rs80358810). A risk-benefit analysis using a questionnaire-based survey was performed in parallel to determine genetic professionals\u2019 views regarding POC testing. This was done to bridge the clinical implementation gap between haplotype analysis and POC testing as a first-tier screen during risk stratification of breast and ovarian cancer patients. The results reflected high acceptance (94%) of <jats:italic>BRCA1\/2<\/jats:italic> POC testing when accompanied by genetic counselling. Establishing the founder status for several recurrent <jats:italic>BRCA2<\/jats:italic> variants across ethnic groups supports unselected use of the BRCA POC assay in all SA breast\/ovarian cancer patients by recent local and international public health recommendations. Incorporating POC genotyping into the planned NGS screening algorithm of the Department of Health will ensure optimal use of the country\u2019s recourses to adhere to the set standards for optimal care and management for all breast cancer patients.<\/jats:p>","DOI":"10.3389\/fonc.2020.619469","type":"journal-article","created":{"date-parts":[[2021,2,13]],"date-time":"2021-02-13T22:46:01Z","timestamp":1613256361000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Globally Rare BRCA2 Variants With Founder Haplotypes in the South African Population: Implications for Point-of-Care Testing Based on a Single-Institution BRCA1\/2 Next-Generation Sequencing Study"],"prefix":"10.3389","volume":"10","author":[{"given":"Jaco","family":"Oosthuizen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maritha J.","family":"Kotze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Van Der Merwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ettienne J.","family":"Myburgh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Bester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nerina C.","family":"van der Merwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,2,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.09.023","article-title":"The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and\u00a0BRCA2","volume":"20","author":"Lakhani","year":"2002","journal-title":"J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1097\/01.pas.0000213351.49767.0f","article-title":"BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays","volume":"31","author":"Bane","year":"2007","journal-title":"Am J Surg Path"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.6231","article-title":"Clinical and pathologic characteristics of patients with BRCA positive and BRCA negative breast cancer","volume":"26","author":"Atchley","year":"2008","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"R95","DOI":"10.1186\/bcr2776","article-title":"Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancer","volume":"12","author":"Tung","year":"2010","journal-title":"Breast Cancer Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s10689-010-9362-5","article-title":"The contribution of breast cancer pathology to statistical models to predict mutation risk in BRCA carriers","volume":"9","author":"Vargas","year":"2010","journal-title":"Fam Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1126\/science.2270482","article-title":"Linkage of early-onset familial breast cancer to chromosome 17q21","volume":"250","author":"Hall","year":"1990","journal-title":"Science"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/378789a0","article-title":"Identification of the breast cancer susceptibility gene BRCA2","volume":"378","author":"Wooster","year":"1995","journal-title":"Nature"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.ss6615a1","article-title":"BRCA genetic testing and receipt of preventive interventions among women aged 18\u201364 years with employer-sponsored health insurance in nonmetropolitan and metropolitan areas \u2013 United States, 2009\u20132014","volume":"66","author":"Kolor","year":"2017","journal-title":"MMWR Surveill Summ"},{"key":"B10","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1186\/1471-2164-14-644","article-title":"Genetic diversity in black South Africans from Soweto","volume":"14","author":"May","year":"2013","journal-title":"BMC Genomics"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.7196\/SAMJ.7215","article-title":"Fanconi anaemia in black South African patients heterozygous for the FANCG c.637-643delTACCGCC founder mutation","volume":"103","author":"Wainstein","year":"2013","journal-title":"S Afr Med J"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.7196\/SAMJnew.8041","article-title":"Understanding the genetic diversity of South Africa\u2019s peoples","volume":"105","author":"Krause","year":"2015","journal-title":"S Afr Med J"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2019.00905","article-title":"Population structure and implications on the genetic architecture of HIV-1 phenotypes within Southern Africa","volume":"10","author":"Thami","year":"2019","journal-title":"Front Genet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12915-020-0746-1","article-title":"Patterns of African and Asian admixture in the Afrikaner population of South Africa","volume":"18","author":"Hollfelder","year":"2020","journal-title":"BMC Biol"},{"key":"B15","unstructured":"MampunyeL\n          Cape TownCape Peninsula University of TechnologyMammaPrint risk score distribution in breast cancer patients with BRCA1\/2 mutations. MSc dissertation2020"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1093\/nar\/16.3.1215","article-title":"A simple salting out procedure for extracting DNA from human nucleated cells","volume":"16","author":"Miller","year":"1988","journal-title":"Nucleic Acids Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0004.2010.01617x","article-title":"A founder BRCA2 mutation in non-Afrikaner breast cancer patients of the Western Cape of South Africa","volume":"81","author":"Van der Merwe","year":"2012","journal-title":"Clin Genet"},{"key":"B18","unstructured":"OosthuizenJ\n          BloemfonteinUniversity of the Free StateMolecular screening of Coloured South African breast cancer patients for the presence of BRCA mutations using high resolution melting analysis. MMedSc dissertation2016"},{"key":"B19","article-title":"The status quo of diagnostics for familial breast cancer in South Africa","volume-title":"18th Biennial congress of the Southern Society for Human Genetics (SASHG)","author":"Van der Merwe","year":"2019"},{"key":"B20","volume-title":"ALFA: Allele Frequency Aggregator","author":"Phan","year":"2020"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/bth457","article-title":"Haploview: analysis and visualization of LD and haplotype maps","volume":"21","author":"Barrett","year":"2005","journal-title":"Bioinformatics"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1126\/science.1069424","article-title":"The structure of haplotype blocks in the human genome","volume":"296","author":"Gabriel","year":"2002","journal-title":"Science"},{"key":"B23","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1186\/s12885-020-06917-y","article-title":"The contribution of large genomic rearrangements in BRCA1 and BRCA2 to South African familial breast cancer","volume":"20","author":"Van der Merwe","year":"2020","journal-title":"BMC Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s10689-017-9968-y","article-title":"Biallelic BRCA2 mutations in two black South African children with Fanconi anaemia","volume":"16","author":"Feben","year":"2017","journal-title":"Fam Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"6491","DOI":"10.1038\/s41598-020-63100-w","article-title":"Founder BRCA1\/BRCA2\/PALB2 pathogenic variants in French-Canadian breast cancer cases and controls","volume":"10","author":"Behl","year":"2020","journal-title":"Sci Rep"},{"key":"B26","doi-asserted-by":"publisher","first-page":"7669","DOI":"10.1038\/s41598-020-63466-x","article-title":"Identifying Ashkenazi Jewish BRCA1\/2 founder variants in individuals who do not self-report Jewish ancestry","volume":"10","author":"Tennen","year":"2020","journal-title":"Sci Rep"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2016.0037","article-title":"Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology","volume":"14","author":"Gradishar","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/humu.22428","article-title":"Functional analysis of a large set of BRCA2 exon 7 variants highlights the predictive value of hexamer scores in detecting alterations of exonic splicing regulatory elements","volume":"34","author":"Di Giacomo","year":"2013","journal-title":"Hum Mutat"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2012-100965","article-title":"Multiple sequence variants of BRCA2 exon 7 alter splicing regulation","volume":"49","author":"Gaildrat","year":"2012","journal-title":"J Med Gen"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1913-6","article-title":"BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and\/or triple negative breast cancer","volume":"15","author":"Francies","year":"2015","journal-title":"BMC Cancer"},{"key":"B31","unstructured":"ChenW\n          JohannesburgUniversity of the WitwatersrandThe molecular aetiology of inherited breast cancer in the South African Black population. MScMed dissertation2015"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.1626","article-title":"German Consortium for Hereditary Breast and Ovarian cancer. Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population","volume":"97","author":"Meindl","year":"2002","journal-title":"Int J Cancer"},{"key":"B33","unstructured":"AgenbagG\n          StellenboschUniversity of StellenboschMolecular genetic analysis of familial breast cancer in South Africa. MSc dissertation2005"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/mutage\/ges069","article-title":"Effect of the expression of BRCA2 on spontaneous homologous recombination and DNA damage-induced nuclear foci in Saccharomyces cerevisiae","volume":"28","author":"Spugnesi","year":"2013","journal-title":"Mutagenesis"},{"key":"B35","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3747\/co.v16i5.529","article-title":"Hereditary breast\/ovarian cancer and BRCA mutations: A South African perspective","volume":"16","author":"Van der Merwe","year":"2009","journal-title":"Curr Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/nature03234","article-title":"The BRCA2 homologue Brh2 nucleates RAD51 filament formation at a dsDNA-ssDNA junction","volume":"433","author":"Yang","year":"2005","journal-title":"Nature"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1126\/science.297.5588.1837","article-title":"BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure","volume":"297","author":"Yang","year":"2002","journal-title":"Science"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1126\/science.1088759","article-title":"New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2","volume":"302","author":"King","year":"2003","journal-title":"Science"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29041","article-title":"Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian","volume":"121","author":"Mersch","year":"2015","journal-title":"Cancer"},{"key":"B40","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1080\/07399331003611442","article-title":"Cancer perceptions of South African mothers and daughters: implications for health promotions programs","volume":"31","author":"Mosavel","year":"2010","journal-title":"Health Care Women Int"},{"key":"B41","first-page":"1","volume-title":"Clinical guidelines for breast cancer control and management","year":"2018"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.7196\/samj.7223","article-title":"MammaPrint Prescreen Algorithm (MPA) reduces chemotherapy in patients with early stage breast cancer","volume":"103","author":"Grant","year":"2013","journal-title":"S Afr Med J"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.17159\/sajs.2019\/5461","article-title":"Reclassification of early stage breast cancer into treatment groups by combining the use of immunohistochemistry and microarray assays","volume":"115","author":"Grant","year":"2019","journal-title":"S Afr J Sci"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s11011-012-9312-z","article-title":"CYP2D6 genotyping and use of antidepressants in breast cancer patients: test development for clinical application","volume":"27","author":"Van der Merwe","year":"2012","journal-title":"Metab Brain Dis"},{"key":"B45","doi-asserted-by":"publisher","first-page":"467","DOI":"10.3390\/ijms18020467","article-title":"Exome sequencing in a family with luminal-type breast cancer underpinned by variation in the methylation pathway","volume":"18","author":"Van der Merwe","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B46","first-page":"54","article-title":"NCCN Breast Cancer Practice Guidelines Panel. NCCN: Breast cancer","volume":"8","author":"Carlson","year":"2001","journal-title":"Cancer Control"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S189627","article-title":"A systematic review of international guidelines and recommendations for the genetic screening, diagnosis. Genetic counselling, and treatment of BRCA-mutated breast cancer","volume":"11","author":"Forbes","year":"2019","journal-title":"Cancer Manag Res"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3109\/10408363.2014.997930","article-title":"Genomic medicine and risk prediction across the disease spectrum","volume":"52","author":"Kotze","year":"2015","journal-title":"Crit Rev Clin Lab Sci"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.3323","article-title":"A cost-effectiveness analysis of multigene testing for all patients with breast\u00a0cancer","volume":"5","author":"Sun","year":"2019","journal-title":"JAMA Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.7196\/samj.6814","article-title":"Implementation of a breast cancer genetic service in South Africa \u2013 lessons learned","volume":"103","author":"Schoeman","year":"2013","journal-title":"S Afr Med J"},{"key":"B51","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1038\/ejhg.2010.249","article-title":"Genetic testing and common disorders in a public health framework: how to assess relevance and possibilities. Background Document to the ESHG recommendations on genetic testing and common disorders","volume":"19","author":"Becker","year":"2011","journal-title":"Eur J Hum Genet"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-17-1144","article-title":"Common genetic variation and breast cancer risk \u2013 past, present, and future","volume":"27","author":"Lilyquist","year":"2018","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1101\/gr.1837404","article-title":"Haplotype block\u00a0partitioning and tag SNP selection using genotype data and their applications to association studies","volume":"14","author":"Zhang","year":"2004","journal-title":"Genome Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2020.619469\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,13]],"date-time":"2021-02-13T22:46:13Z","timestamp":1613256373000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2020.619469\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,12]]},"references-count":53,"alternative-id":["10.3389\/fonc.2020.619469"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.619469","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,12]]},"article-number":"619469"}}